Advanced search
Publication Cover
Leukemia & Lymphoma Volume 56, 2015 - Issue 11
Submit an article Journal homepage
418
Views
17
CrossRef citations to date
0
Altmetric
Original Articles: Clinical

Phase I study of the anti-CD74 monoclonal antibody milatuzumab (hLL1) in patients with previously treated B-cell lymphomas

Peter MartinDepartment of Medicine, Weill Cornell Medical College, New York, NY, USACorrespondence[email protected]
,
Richard R. FurmanDepartment of Medicine, Weill Cornell Medical College, New York, NY, USA
,
Sarah RutherfordDepartment of Medicine, Weill Cornell Medical College, New York, NY, USA
,
Jia RuanDepartment of Medicine, Weill Cornell Medical College, New York, NY, USA
,
Scott ElyPathology and Laboratory Medicine, Weill Cornell Medical College, New York, NY, USA
,
June GreenbergDepartment of Medicine, Weill Cornell Medical College, New York, NY, USA
,
Morton ColemanDepartment of Medicine, Weill Cornell Medical College, New York, NY, USA
,
Stanley J. GoldsmithDepartment of Radiology, Weill Cornell Medical College, New York, NY, USA
&
John P. LeonardDepartment of Medicine, Weill Cornell Medical College, New York, NY, USA
 show all
Pages 3065-3070 | Received 17 Nov 2014, Accepted 05 Mar 2015, Published online: 12 May 2015

References

  • Martin P, Furman RR, Coleman M, et al. Phase I to III trials of anti B cell therapy in non Hodgkin's lymphoma. Clin Cancer Res 2007;13:5636s–5642s.
  • Gold D, Stein R, Burton J, et al. Enhanced expression of CD74 in gastrointestinal cancers and benign tissues. Int J Clin Exp Pathol 2011;4:1–12.
  • Borghese F, Clanchy FI. CD74: an emerging opportunity as a therapeutic target in cancer and autoimmune disease. Expert Opin Ther Targets 2011;15:237–51.
  • Cresswell P. Assembly, transport, and function of MHC class II molecules. Annu Rev Immunol 1994;12:259–291.
  • Stein R, Mattes MJ, Cardillo TM, et al. CD74: a new candidate target for the immunotherapy of B-cell neoplasms. Clin Cancer Res 2007;13:5556s–5563s.
  • Shachar I, Haran M. The secret second life of an innocent chaperone: the story of CD74 and B cell/chronic lymphocytic leukemia cell survival. Leuk Lymphoma 2011;52:1446–1454.
  • Mark T, Martin P, Leonard JP, et al. Milatuzumab: a promising new agent for the treatment of lymphoid malignancies. Expert Opin Investig Drugs 2009;18:99–104.
  • Kaufman JL, Niesvizky R, Stadtmauer EA, et al. Phase I, multicentre, dose-escalation trial of monotherapy with milatuzumab (humanized anti-CD74 monoclonal antibody) in relapsed or refractory multiple myeloma. Br J Haematol 2013;163:478–486.
  • Ong GL, Goldenberg DM, Hansen HJ, et al. Cell surface expression and metabolism of major histocompatibility complex class II invariant chain (CD74) by diverse cell lines. Immunology 1999;98:296–302.
  • Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007;25:579–586.
  • Hallek M, Cheson BD, Catovsky D, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 2008;111:5446–5456.
  • Love C, Palestro CJ. Radionuclide imaging of infection. J Nucl Med Technol 2004;32:47–57.
  • Mao Y, Triantafillou G, Hertlein E, et al. Milatuzumab-conjugated liposomes as targeted dexamethasone carriers for therapeutic delivery in CD74 + B-cell malignancies. Clin Cancer Res 2013;19:347–356.
  • Govindan SV, Cardillo TM, Sharkey RM, et al. Milatuzumab–SN-38 conjugates for the treatment of CD74 + cancers. Mol Cancer Ther 2013;12:968–978.
  • Gupta P, Goldenberg DM, Rossi EA, et al. Dual-targeting immunotherapy of lymphoma: potent cytotoxicity of anti-CD20/CD74 bispecific antibodies in mantle cell and other lymphomas. Blood 2012;119:3767–3778.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.